A novel hepatitis B vaccine containing Advax™, a polysaccharide adjuvant derived from delta inulin, induces robust humoral and cellular immunity with minimal reactogenicity in preclinical testing

► Advax adjuvant provided HBs dose-sparing when compared to alum. ► Advax induced strong anti-HBs CD4 and CD8T cell responses. ► Advax simultaneously enhanced Th1, Th2 and Th17 responses. ► Unlike alum, Advax worked even when injected 24 h before the antigen.